{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T10:59:51Z","timestamp":1756810791581},"reference-count":30,"publisher":"Japanese Society of Internal Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,4,1]]},"DOI":"10.2169\/internalmedicine.9529-22","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T22:09:44Z","timestamp":1662415784000},"page":"1081-1087","source":"Crossref","is-referenced-by-count":3,"title":["Anti-MDA-5 Antibody-positive Dermatomyositis after Allogeneic Bone Marrow Transplantation for Acute Transformation of Chronic Myelogenous Leukemia"],"prefix":"10.2169","volume":"62","author":[{"given":"Mariko","family":"Futamura","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kansai Medical University Hospital, Japan"},{"name":"First Department of Internal Medicine, Kansai Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kansai Medical University Hospital, Japan"},{"name":"First Department of Internal Medicine, Kansai Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidehiko","family":"Makino","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kansai Medical University Hospital, Japan"},{"name":"Department of Rheumatology, Osaka Medical and Pharmaceutical University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saki","family":"Tsujimoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kansai Medical University Hospital, Japan"},{"name":"First Department of Internal Medicine, Kansai Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Shigesaka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kansai Medical University Hospital, Japan"},{"name":"First Department of Internal Medicine, Kansai Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kansai Medical University Hospital, Japan"},{"name":"First Department of Internal Medicine, Kansai Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Shimamoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kansai Medical University Hospital, Japan"},{"name":"First Department of Internal Medicine, Kansai Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonsu","family":"Son","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kansai Medical University Hospital, Japan"},{"name":"First Department of Internal Medicine, Kansai Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Ito","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Kansai Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shosaku","family":"Nomura","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Kansai Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52: 1571-1576, 2005.","DOI":"10.1002\/art.21023"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Tsuji H, Nakashima R, Hosono Y, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol 72: 488-498, 2020.","DOI":"10.1002\/art.41105"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Gonzalez-Vicent M, Sanz J, Fuster JL, et al. Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): a retrospective analysis and a proposal of treatment on behalf of the Grupo Espanol De Trasplante de Medula Osea en Ninos (GETMON) and the Grupo Espanol de Trasplante Hematopoyetico (GETH). Transfus Med Rev 32: 179-185, 2018.","DOI":"10.1016\/j.tmrv.2018.02.005"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Faraci M, Zecca M, Pillon M, et al. Autoimmune hematological diseases after allogeneic hematopoietic stem cell transplantation in children: an Italian multicenter experience. Biol Blood Marrow Transplant 20: 272-278, 2014.","DOI":"10.1016\/j.bbmt.2013.11.014"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Sanders JE, Hoffmeister PA, Woolfrey AE, et al. Thyroid function following hematopoietic cell transplantation in children: 30 years&apos; experience. Blood 113: 306-308, 2009.","DOI":"10.1182\/blood-2008-08-173005"},{"key":"6","unstructured":"6. Gomez Garcia P, Herrera Arroyo C, Torres Gomez A, et al. Renal involvement in chronic graft-versus-host disease: a report of two cases. Bone Marrow Transplant 3: 357-362, 1988."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Mackey J, Desai S, Nabholtz J-M, et al. Myasthenia gravis in association with allogeneic bone marrow transplantation: clinical observations, therapeutic implications and review of literature. Bone Marrow Transplant 19: 939-942, 1997.","DOI":"10.1038\/sj.bmt.1700759"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Nakashima R, Imura Y, Kobayashi S, et al. The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) 49: 433-440, 2010.","DOI":"10.1093\/rheumatology\/kep375"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Gono T, Kawaguchi Y, Satoh T, et al. Clinical manifestation and prognostic factor in anti- melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 49: 1713-1719, 2010.","DOI":"10.1093\/rheumatology\/keq149"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hoshino K, Muro Y, Sugiura K, et al. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) 49: 1726-1733, 2010.","DOI":"10.1093\/rheumatology\/keq153"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Gono T, Sato S, Kawaguchi Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford) 51: 1563-1570, 2012.","DOI":"10.1093\/rheumatology\/kes102"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Matsushita T, Mizumaki K, Kano M, et al. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. Br J Dermatol 176: 395-402, 2017.","DOI":"10.1111\/bjd.14882"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 65: 25-34, 2011.","DOI":"10.1016\/j.jaad.2010.09.016"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Parker P, Chao NJ, Ben-Ezra J, et al. Polymyositis as a manifestation of chronic graft-versus-host disease. Medicine (Baltimore) 75: 279-285, 1996.","DOI":"10.1097\/00005792-199609000-00004"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford) 42: 34-39, 2003.","DOI":"10.1093\/rheumatology\/keg025"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Couriel DR, Beguelin GZ, Giralt S, et al. Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentation. Bone Marrow Transplant 30: 432-546, 2002.","DOI":"10.1038\/sj.bmt.1703711"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Leano AM, Miller K, White AC. Chronic graft-versus-host disease-related polymyositis as a cause of respiratory failure following allogeneic bone marrow transplant. Bone Marrow Transplant 26: 1117-1120, 2000.","DOI":"10.1038\/sj.bmt.1702688"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Anderson BA, Young PV, Kean WF, et al. Polymyositis in chronic graft vs host disease. A case report. Arch Neurol 39: 188-190, 1982.","DOI":"10.1001\/archneur.1982.00510150058015"},{"key":"19","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1212\/WNL.36.8.1091","volume":"36","author":"A Urbano-M\u00e1rquez","year":"1986","unstructured":"19. Urbano-M\u00e1rquez A, Estruch R, Grau JM, et al. Inflammatory myopathy associated with chronic graft-versus-host disease. Neurology 36: 1091-1093, 1986.","journal-title":"Neurology","ISSN":"http:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Prussick R, Brain MC, Walker IR, et al. Polymyositis: a manifestation of chronic graft-versus-host disease. J Am Acad Dermatol 25: 560-562, 1991.","DOI":"10.1016\/0190-9622(91)70240-3"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Takahashi K, Kashihara K, Shinagawa K, et al. Myositis as a manifestation of chronic graft-versus-host disease. Intern Med 39: 482-485, 2000.","DOI":"10.2169\/internalmedicine.39.482"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Seconi J, Watt V, Ritchie DS. Nephrotic syndrome following allogeneic stem cell transplantation associated with increased production of TNF-alpha and interferon-gamma by donor T cells. Bone Marrow Transplant 32: 447-450, 2003.","DOI":"10.1038\/sj.bmt.1704151"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Kalwak K, Gorczynska E, Wojcik D, et al. Late-onset idiopathic thrombocytopenic purpura correlates with rapid B-cell recovery after allogeneic T-cell-depleted peripheral blood progenitor cell transplantation in children. Transplant Proc 34: 3374-3377, 2002.","DOI":"10.1016\/S0041-1345(02)03607-2"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Sherer Y, Shoenfield Y. Autoimmune diseases and autoimmunity post-bone marrow transplantation. Bone Marrow Transplant 22: 873-881, 1998.","DOI":"10.1038\/sj.bmt.1701437"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Shiohara T, Kano Y, Hirahara K, et al. Prediction and management of drug reaction with eosinophilia and systemic symptoms (DRESS). Expert Opin Drug Metab Toxicol 13: 701-704, 2017.","DOI":"10.1080\/17425255.2017.1297422"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Kano Y, Hiraharas K, Sakuma K, et al. Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. Br J Dermatol 155: 301-306, 2006.","DOI":"10.1111\/j.1365-2133.2006.07238.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Shiohara T, Kurata M, Mizukawa Y, et al. Recognition of immune reconstitution syndrome necessary for better management of patients with severe drug eruptions and those under immunosuppressive therapy. Allergol Int 59: 333-343, 2010.","DOI":"10.2332\/allergolint.10-RAI-0260"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Ushigome Y, Mizukawa Y, Kimishima M, et al. Monocytes are involved in the balance between regulatory T cells and Th17 cells in severe drug eruptions. Clin Exp Allergy 48: 1453-1463, 2018.","DOI":"10.1111\/cea.13252"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Sato S, Masui K, Nishina N, et al. Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients. Rheumatology (Oxford) 57: 1212-1221, 2018.","DOI":"10.1093\/rheumatology\/key060"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Saito T, Mizobuchi M, Miwa Y, et al. Anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease treated with therapeutic plasma exchange: a case series. J Clin Apher 36: 196-205, 2021.","DOI":"10.1002\/jca.21833"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/7\/62_9529-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:31:52Z","timestamp":1715315512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/7\/62_9529-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9529-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,1]]},"article-number":"9529-22"}}